Emtricitabine/tenofovir disoproxil fumarate vs Tenofovir alafenamide/emtricitabine
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV reverse transcriptase · full HIV pipeline
Emtricitabine/tenofovir disoproxil fumarate · Truvada
Marketed by Gilead Sciences
NCT00323544 · Phase 3 · completed
This was a randomized, open-label, active-controlled trial of 220 participants, comparing Truvada with Combivir. Its primary endpoint was a laboratory measure—change in hemoglobin—not a hard clinical or endoscopic outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: December 2026 · NCT07584122 (registry estimate)
Reported efficacy
The primary endpoint for the study is a change from baseline in absolute haemoglobin at Week 24.: Primary endpoint, week 24 change from baseline in absolute hemoglobin: switching to Truvada+efavirenz vs continuing Combivir+efavirenz, mean difference +0.37 g/dL (95% CI 0.15 to 0.58 g/dL), P<0.001, favoring the switch arm. (met)
Result source: NCT00323544
Tenofovir alafenamide/emtricitabine · Descovy
Marketed by Gilead Sciences
NCT02121795 · Phase 3 · completed
This was a randomized, quadruple-blind, active-controlled trial of 668 participants, with 333 receiving F/TAF and 330 receiving FTC/TDF in the treated analysis. The primary clinical endpoint was met: virologic suppression was 94.3% versus 93.0%, and the prespecified non-inferiority confidence interval remained within the 10% margin.
Next expected readout: January 2027 · NCT07349758 (registry estimate)
Reported efficacy
Incidence of HIV-1 Infection Per 100 Person Years (PY) (When all participants completed minimum follow-up of 48 weeks and at least 50% of the participants completed 96 weeks of follow-up after randomization or permanently discontinued from the study (maximum 125 weeks)): Incidence of HIV-1 Infection Per 100 Person Years (PY) (When all participants completed minimum follow-up of 48 weeks and at least 50% of the participants completed 96 weeks of follow-up after randomization or permanently discontinued from the study (maximum 125 weeks)): Descovy (DVY) 0.16 HIV-1 infections per 100 PY (95% CI 0.064 to 0.33) | Truvada (TVD) 0.342 HIV-1 infections per 100 PY (95% CI 0.191 to 0.564) (met)
Result source: NCT02842086
Results for HIV
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Emtricitabine/tenofovir disoproxil fumarate | Tenofovir alafenamide/emtricitabine |
|---|---|---|
| HIV-1 RNA below 50 copies/mL (week 48) | 83.8% vs 79.9%vs Daurunavir + RitonavirNCT022757805 other results
| 94.3% vs 93%vs FTC/TDFNCT0212179531 other results
|
| HIV-1 RNA 50 copies/mL or more (week 48) | —Not posted · NCT00323544 | 0.4% vs 1.1%vs DTG + F/TAFNCT031103802 other results
|
| CD4 count, change (week 48) | 224.1 vs 206.7vs Daurunavir + RitonavirNCT0227578012 other results
| 60 vs 42vs Baseline Treatment Regimen (SBR)NCT0181573636 other results
|
HIV-1 RNA below 50 copies/mL (week 48)
- Emtricitabine/tenofovir disoproxil fumarate
- 83.8% vs 79.9%vs Daurunavir + RitonavirNCT02275780
5 other results
- 85.2% vs 87.4% NCT01108510
- 73.1% vs 66% NCT02275780
- 72.1% vs 74.1% NCT01108510
- 77.9% vs 79.3% NCT01108510
- 71.6% vs 79.7% NCT01108510
- Tenofovir alafenamide/emtricitabine
- 94.3% vs 93%vs FTC/TDFNCT02121795
31 other results
- 88.6% vs 92.4% NCT02469246
- 91.6% vs 88.5% NCT01797445
- 92.4% vs 93% NCT02607930
- 87.2% vs 80.8% NCT01705574
- 93.4% vs 97.8% NCT02605954
- 96.6% vs 97.8% NCT02605954
- 81.5% vs 84.1% NCT02607930
- 88.6% vs 89.1% NCT02121795
- 82.1% vs 88.4% NCT02469246
- 84% vs 82.3% NCT01797445
- 92.8% vs 89.1% NCT01815736
- 87.9% vs 89.8% NCT02607930
- 93.3% vs 91.1% NCT03110380
- 90.4% vs 92% NCT04143594
- 84.9% vs 92% NCT04143594
- 84.6% vs 92% NCT04143594
- 96.9% vs 93.9% NCT02397694
- 88.4% vs 89.7% NCT01497899
- 74.8% vs 74% NCT01565850
- 86.5% vs 92% NCT04143594
- 75.5% vs 92% NCT04143594
- 86.5% vs 92% NCT04143594
- 96.9% vs 90.9% NCT02397694
- 88.4% vs 87.9% NCT01497899
- 76.7% vs 84% NCT01565850
- 90.4% vs 96% NCT04143594
- 88.7% vs 96% NCT04143594
- 88.5% vs 96% NCT04143594
- 94.2% vs 100% NCT04143594
- 92.5% vs 100% NCT04143594
- 94.2% vs 100% NCT04143594
HIV-1 RNA 50 copies/mL or more (week 48)
- Emtricitabine/tenofovir disoproxil fumarate
- —Not posted · NCT00323544
- Tenofovir alafenamide/emtricitabine
- 0.4% vs 1.1%vs DTG + F/TAFNCT03110380
2 other results
- 2.5% vs 1.1% NCT02469246
- 1.8% vs 0.7% NCT02469246
CD4 count, change (week 48)
- Emtricitabine/tenofovir disoproxil fumarate
- 224.1 vs 206.7vs Daurunavir + RitonavirNCT02275780
12 other results
- 192.7 vs 185.6 NCT02275780
- 310 vs 332 NCT01108510
- 277 vs 287 NCT01108510
- 291 vs 256 NCT00089505
- 223 vs 256 NCT00089505
- 213 vs 219 NCT01108510
- 172 vs 172 NCT00089505
- 350 vs 343 NCT01108510
- 191 vs 172 NCT00089505
- 158 vs 146 NCT01380080
- 96 vs 102 NCT01380080
- 8 vs 34 NCT00724711
- Tenofovir alafenamide/emtricitabine
- 60 vs 42vs Baseline Treatment Regimen (SBR)NCT01815736
36 other results
- 278 vs 289 NCT02607956
- 299 vs 317 NCT02607930
- 50 vs 46 NCT02121795
- -29 vs 10 NCT02469246
- 274 vs 260 NCT01797445
- 237 vs 281 NCT02607956
- 287 vs 288 NCT02607930
- 20 vs 21 NCT02121795
- -30 vs 2 NCT02469246
- 225 vs 200 NCT01797445
- 180 vs 201 NCT02607956
- 235 vs 228 NCT02607930
- 18 vs 36 NCT03110380
- 221 vs 212 NCT01705574
- 56 vs -1 NCT02616783
- 5 vs 41 NCT01968551
- 48 vs -4 NCT02616783
- -28 vs 8 NCT02605954
- -23 vs 8 NCT02605954
- 23 vs 12 NCT01968551
- 275 vs 248 NCT04143594
- 262 vs 248 NCT04143594
- 245 vs 248 NCT04143594
- 204 vs 193 NCT04143594
- 213 vs 193 NCT04143594
- 220 vs 193 NCT04143594
- 177 vs 204 NCT01497899
- 231 vs 212 NCT01565850
- 195 vs 232 NCT04143594
- 220 vs 232 NCT04143594
- 211 vs 232 NCT04143594
- 172 vs 163 NCT04143594
- 158 vs 163 NCT04143594
- 206 vs 163 NCT04143594
- 165 vs 179 NCT01497899
- 186 vs 139 NCT01565850
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety
Coverage. Emtricitabine/tenofovir disoproxil fumarate: 6 of 6 rows · Tenofovir alafenamide/emtricitabine: 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Emtricitabine/tenofovir disoproxil fumarate Rows use multiple source trials | Tenofovir alafenamide/emtricitabine Rows use multiple source trials |
|---|---|---|
| CD4 absolute change · count Maintenance | 189.1 vs 163.3 Efavirenz count @ 48wk400 mg b.i.d.a,b,c NCT00369941 · Phase 3 · registry result, not featured evidence | 258 vs 188 DTG + F/TAF count @ 48wka,b,c NCT02397694 · Phase 2 · registry result, not featured evidence · combination |
| HIV-1 RNA LT 50 Copies responder rate · % of participants Maintenance | 93% (n=154) vs 91.1% (n=156) ABC/3TC @ 48wkd,b NCT00724711 · Phase 4 · registry result, not featured evidence · combination | 94.4% (n=89) vs 76.1% (n=46) SBR @ 48wkd,b NCT01968551 · Phase 3 · registry result, not featured evidence · combination |
| Dropout rate | 24.7%e NCT00458393 · Phase 3 show 15 more results16%Rectal Gel Lubricant + Truvada NCT02401230 · Phase 4 · registry result, not featured evidence · combination 24%Truvada NCT02401230 · Phase 4 · registry result, not featured evidence 20% NCT01380080 · Phase 4 · registry result, not featured evidence — NCT00724711 · Phase 4 · registry result, not featured evidence · combination 0%200/300 mg, Daily, by Mouth NCT00960622 · Phase 4 · registry result, not featured evidence —Truvada NCT00960622 · Phase 4 · registry result, not featured evidence — NCT00323492 · Phase 4 · registry result, not featured evidence 24.2%100 mg NCT02275780 · Phase 3 · registry result, not featured evidence —1200 mg QD + Truvada NCT02131233 · Phase 3 · registry result, not featured evidence · combination 79.9% NCT01108510 · Phase 3 · registry result, not featured evidence · combination 25% NCT01195467 · Phase 3 · registry result, not featured evidence 19.5% NCT00625404 · Phase 3 · registry result, not featured evidence 25.5%400 mg b.i.d. NCT00369941 · Phase 3 · registry result, not featured evidence 7.4%NVP/NVP NCT00089505 · Phase 3 · registry result, not featured evidence 8.4%NoNVP/NVP NCT00089505 · Phase 3 · registry result, not featured evidence | 11.4%F/TAF + 3rd Agentf NCT02121795 · Phase 3 · combination show 52 more results—F/TAF + 3rd Agent (Double-Blind) NCT02121795 · Phase 3 · combination —Open-Label F/TAF From F/TAF NCT02121795 · Phase 3 —Open-Label F/TAF From FTC/TDF NCT02121795 · Phase 3 23.5%F/TAF NCT02469246 · Phase 3 —F/TAF (Double-Blind Phase) NCT02469246 · Phase 3 —Open-Label F/TAF From ABC/3TC NCT02469246 · Phase 3 —Open-Label F/TAF From F/TAF NCT02469246 · Phase 3 20%E/C/F/TAF NCT01797445 · Phase 3 —E/C/F/TAF (Double-Blind Phase) NCT01797445 · Phase 3 —Open-Label E/C/F/TAF From E/C/F/TA NCT01797445 · Phase 3 —Open-Label E/C/F/TAF From E/C/F/TD NCT01797445 · Phase 3 5.1%E/C/F/TAF NCT01815736 · Phase 3 —Extension Phase: E/C/F/TAF From E/ NCT01815736 · Phase 3 —Extension Phase: E/C/F/TAF From SB NCT01815736 · Phase 3 —Randomized Phase: E/C/F/TAF NCT01815736 · Phase 3 12.6%Cohort 1 (Treatment-experienced) NCT01818596 · Phase 3 0%Cohort 2 (Treatment-naive) NCT01818596 · Phase 3 4%Cohort 1: Age 12 to < 18 Years and NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3 1.9%Cohort 2: Age 6 to < 12 Years and NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3 0%Cohort 3: Age ≥ 2 Years and Weight NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3 4.4% NCT04782180 · Phase 4 · registry result, not featured evidence 18.7% NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3 17.1%B/F/TAF NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —B/F/TAF to B/F/TAF NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3 7.4%B/F/TAF NCT03110380 · Phase 3 · registry result, not featured evidence —Double-Blind Treatment Phase B/F/T NCT03110380 · Phase 3 · registry result, not featured evidence —Open-label Extension Phase B/F/TAF NCT03110380 · Phase 3 · registry result, not featured evidence —Open-label Extension Phase B/F/TAF NCT03110380 · Phase 3 · registry result, not featured evidence · combination —DB STB to OL STB NCT01705574 · Phase 3 · registry result, not featured evidence —Double-Blind: STB NCT01705574 · Phase 3 · registry result, not featured evidence 5.4% NCT02616783 · Phase 3 · registry result, not featured evidence —Delayed E/C/F/TAF NCT02605954 · Phase 3 · registry result, not featured evidence 6.6%E/C/F/TAF NCT02605954 · Phase 3 · registry result, not featured evidence 5.3%E/C/F/TAF + LDV/SOF NCT02707601 · Phase 3 · registry result, not featured evidence · combination 5.4%F/R/TAF + LDV/SOF NCT02707601 · Phase 3 · registry result, not featured evidence · combination 0%Part 1 Randomized Cohort TAF NCT01967940 · Phase 3 · registry result, not featured evidence 0%Part 1 Sentinel Cohort TAF NCT01967940 · Phase 3 · registry result, not featured evidence —Part 2 E/C/F/TAF + ATV NCT01967940 · Phase 3 · registry result, not featured evidence · combination —HIV-Suppressed NCT02071082 · Phase 3 · registry result, not featured evidence —HIV/HBV Treatment-Naive NCT02071082 · Phase 3 · registry result, not featured evidence 9.1%Cohort 1: E/C/F/TAF+DRV NCT01968551 · Phase 3 · registry result, not featured evidence · combination 3.3%Cohort 2: E/C/F/TAF+DRV NCT01968551 · Phase 3 · registry result, not featured evidence · combination 8%E/C/F/TAF (12 - 17 Years of Age) NCT02276612 · Phase 2/3 · registry result, not featured evidence 0%E/C/F/TAF (≥ 18 Years of Age) NCT02276612 · Phase 2/3 · registry result, not featured evidence 21.2%Group 1: SC LEN+(F/TAF→ TAF) NCT04143594 · Phase 2 · registry result, not featured evidence · combination 34%Group 2: SC LEN + (F/TAF → BIC) NCT04143594 · Phase 2 · registry result, not featured evidence · combination 30.8%Group 3: Oral LEN + F/TAF NCT04143594 · Phase 2 · registry result, not featured evidence · combination 4.6%BIC + F/TAF NCT02397694 · Phase 2 · registry result, not featured evidence · combination —BIC + F/TAF (Double-Blind Randomiz NCT02397694 · Phase 2 · registry result, not featured evidence · combination 5.3% NCT01497899 · Phase 2 · registry result, not featured evidence 19.4% NCT01565850 · Phase 2 · registry result, not featured evidence 3% NCT03960645 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —e NCT00458393 · Phase 3 show 15 more results0%Rectal Gel Lubricant + Truvada NCT02401230 · Phase 4 · registry result, not featured evidence · combination 8%Truvada NCT02401230 · Phase 4 · registry result, not featured evidence — NCT01380080 · Phase 4 · registry result, not featured evidence — NCT00724711 · Phase 4 · registry result, not featured evidence · combination —200/300 mg, Daily, by Mouth NCT00960622 · Phase 4 · registry result, not featured evidence —Truvada NCT00960622 · Phase 4 · registry result, not featured evidence — NCT00323492 · Phase 4 · registry result, not featured evidence 1.6%100 mg NCT02275780 · Phase 3 · registry result, not featured evidence —1200 mg QD + Truvada NCT02131233 · Phase 3 · registry result, not featured evidence · combination 7.4% NCT01108510 · Phase 3 · registry result, not featured evidence · combination — NCT01195467 · Phase 3 · registry result, not featured evidence — NCT00625404 · Phase 3 · registry result, not featured evidence 5%400 mg b.i.d. NCT00369941 · Phase 3 · registry result, not featured evidence —NVP/NVP NCT00089505 · Phase 3 · registry result, not featured evidence —NoNVP/NVP NCT00089505 · Phase 3 · registry result, not featured evidence | 1.5%F/TAF + 3rd Agentf NCT02121795 · Phase 3 · combination show 52 more results—F/TAF + 3rd Agent (Double-Blind) NCT02121795 · Phase 3 · combination —Open-Label F/TAF From F/TAF NCT02121795 · Phase 3 —Open-Label F/TAF From FTC/TDF NCT02121795 · Phase 3 4.2%F/TAF NCT02469246 · Phase 3 —F/TAF (Double-Blind Phase) NCT02469246 · Phase 3 —Open-Label F/TAF From ABC/3TC NCT02469246 · Phase 3 —Open-Label F/TAF From F/TAF NCT02469246 · Phase 3 0.7%E/C/F/TAF NCT01797445 · Phase 3 —E/C/F/TAF (Double-Blind Phase) NCT01797445 · Phase 3 —Open-Label E/C/F/TAF From E/C/F/TA NCT01797445 · Phase 3 —Open-Label E/C/F/TAF From E/C/F/TD NCT01797445 · Phase 3 0.7%E/C/F/TAF NCT01815736 · Phase 3 —Extension Phase: E/C/F/TAF From E/ NCT01815736 · Phase 3 —Extension Phase: E/C/F/TAF From SB NCT01815736 · Phase 3 —Randomized Phase: E/C/F/TAF NCT01815736 · Phase 3 2.8%Cohort 1 (Treatment-experienced) NCT01818596 · Phase 3 0%Cohort 2 (Treatment-naive) NCT01818596 · Phase 3 —Cohort 1: Age 12 to < 18 Years and NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3 —Cohort 2: Age 6 to < 12 Years and NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3 —Cohort 3: Age ≥ 2 Years and Weight NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3 — NCT04782180 · Phase 4 · registry result, not featured evidence 1.2% NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3 0%B/F/TAF NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —B/F/TAF to B/F/TAF NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3 1.1%B/F/TAF NCT03110380 · Phase 3 · registry result, not featured evidence —Double-Blind Treatment Phase B/F/T NCT03110380 · Phase 3 · registry result, not featured evidence —Open-label Extension Phase B/F/TAF NCT03110380 · Phase 3 · registry result, not featured evidence —Open-label Extension Phase B/F/TAF NCT03110380 · Phase 3 · registry result, not featured evidence · combination —DB STB to OL STB NCT01705574 · Phase 3 · registry result, not featured evidence —Double-Blind: STB NCT01705574 · Phase 3 · registry result, not featured evidence 0.9% NCT02616783 · Phase 3 · registry result, not featured evidence —Delayed E/C/F/TAF NCT02605954 · Phase 3 · registry result, not featured evidence 2.7%E/C/F/TAF NCT02605954 · Phase 3 · registry result, not featured evidence —E/C/F/TAF + LDV/SOF NCT02707601 · Phase 3 · registry result, not featured evidence · combination —F/R/TAF + LDV/SOF NCT02707601 · Phase 3 · registry result, not featured evidence · combination —Part 1 Randomized Cohort TAF NCT01967940 · Phase 3 · registry result, not featured evidence —Part 1 Sentinel Cohort TAF NCT01967940 · Phase 3 · registry result, not featured evidence —Part 2 E/C/F/TAF + ATV NCT01967940 · Phase 3 · registry result, not featured evidence · combination —HIV-Suppressed NCT02071082 · Phase 3 · registry result, not featured evidence —HIV/HBV Treatment-Naive NCT02071082 · Phase 3 · registry result, not featured evidence —Cohort 1: E/C/F/TAF+DRV NCT01968551 · Phase 3 · registry result, not featured evidence · combination —Cohort 2: E/C/F/TAF+DRV NCT01968551 · Phase 3 · registry result, not featured evidence · combination —E/C/F/TAF (12 - 17 Years of Age) NCT02276612 · Phase 2/3 · registry result, not featured evidence —E/C/F/TAF (≥ 18 Years of Age) NCT02276612 · Phase 2/3 · registry result, not featured evidence 1.9%Group 1: SC LEN+(F/TAF→ TAF) NCT04143594 · Phase 2 · registry result, not featured evidence · combination 0%Group 2: SC LEN + (F/TAF → BIC) NCT04143594 · Phase 2 · registry result, not featured evidence · combination 0%Group 3: Oral LEN + F/TAF NCT04143594 · Phase 2 · registry result, not featured evidence · combination 1.5%BIC + F/TAF NCT02397694 · Phase 2 · registry result, not featured evidence · combination —BIC + F/TAF (Double-Blind Randomiz NCT02397694 · Phase 2 · registry result, not featured evidence · combination 0.9% NCT01497899 · Phase 2 · registry result, not featured evidence 0% NCT01565850 · Phase 2 · registry result, not featured evidence — NCT03960645 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 7.5%e NCT00458393 · Phase 3 show 15 more results0%Rectal Gel Lubricant + Truvada NCT02401230 · Phase 4 · registry result, not featured evidence · combination 0%Truvada NCT02401230 · Phase 4 · registry result, not featured evidence 20% NCT01380080 · Phase 4 · registry result, not featured evidence 7.7% NCT00724711 · Phase 4 · registry result, not featured evidence · combination —200/300 mg, Daily, by Mouth NCT00960622 · Phase 4 · registry result, not featured evidence 0%Truvada NCT00960622 · Phase 4 · registry result, not featured evidence 9.7% NCT00323492 · Phase 4 · registry result, not featured evidence 11.7%100 mg NCT02275780 · Phase 3 · registry result, not featured evidence 9.6%1200 mg QD + Truvada NCT02131233 · Phase 3 · registry result, not featured evidence · combination 18.6% NCT01108510 · Phase 3 · registry result, not featured evidence · combination 10% NCT01195467 · Phase 3 · registry result, not featured evidence 3.2% NCT00625404 · Phase 3 · registry result, not featured evidence 20.3%400 mg b.i.d. NCT00369941 · Phase 3 · registry result, not featured evidence 7.4%NVP/NVP NCT00089505 · Phase 3 · registry result, not featured evidence 10.4%NoNVP/NVP NCT00089505 · Phase 3 · registry result, not featured evidence | —F/TAF + 3rd Agentf NCT02121795 · Phase 3 · combination show 52 more results8.7%F/TAF + 3rd Agent (Double-Blind) NCT02121795 · Phase 3 · combination 6.1%Open-Label F/TAF From F/TAF NCT02121795 · Phase 3 9.7%Open-Label F/TAF From FTC/TDF NCT02121795 · Phase 3 —F/TAF NCT02469246 · Phase 3 19.6%F/TAF (Double-Blind Phase) NCT02469246 · Phase 3 0%Open-Label F/TAF From ABC/3TC NCT02469246 · Phase 3 0%Open-Label F/TAF From F/TAF NCT02469246 · Phase 3 —E/C/F/TAF NCT01797445 · Phase 3 12.5%E/C/F/TAF (Double-Blind Phase) NCT01797445 · Phase 3 2.8%Open-Label E/C/F/TAF From E/C/F/TA NCT01797445 · Phase 3 1.7%Open-Label E/C/F/TAF From E/C/F/TD NCT01797445 · Phase 3 —E/C/F/TAF NCT01815736 · Phase 3 3%Extension Phase: E/C/F/TAF From E/ NCT01815736 · Phase 3 5.2%Extension Phase: E/C/F/TAF From SB NCT01815736 · Phase 3 8.2%Randomized Phase: E/C/F/TAF NCT01815736 · Phase 3 22.7%Cohort 1 (Treatment-experienced) NCT01818596 · Phase 3 16.7%Cohort 2 (Treatment-naive) NCT01818596 · Phase 3 20%Cohort 1: Age 12 to < 18 Years and NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3 13.5%Cohort 2: Age 6 to < 12 Years and NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3 3.7%Cohort 3: Age ≥ 2 Years and Weight NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3 0% NCT04782180 · Phase 4 · registry result, not featured evidence 20% NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3 14%B/F/TAF NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3 7.5%B/F/TAF to B/F/TAF NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —B/F/TAF NCT03110380 · Phase 3 · registry result, not featured evidence 12.7%Double-Blind Treatment Phase B/F/T NCT03110380 · Phase 3 · registry result, not featured evidence 9.6%Open-label Extension Phase B/F/TAF NCT03110380 · Phase 3 · registry result, not featured evidence 9.5%Open-label Extension Phase B/F/TAF NCT03110380 · Phase 3 · registry result, not featured evidence · combination 5.3%DB STB to OL STB NCT01705574 · Phase 3 · registry result, not featured evidence 8.7%Double-Blind: STB NCT01705574 · Phase 3 · registry result, not featured evidence 9.1% NCT02616783 · Phase 3 · registry result, not featured evidence 4.5%Delayed E/C/F/TAF NCT02605954 · Phase 3 · registry result, not featured evidence 6.6%E/C/F/TAF NCT02605954 · Phase 3 · registry result, not featured evidence 9.5%E/C/F/TAF + LDV/SOF NCT02707601 · Phase 3 · registry result, not featured evidence · combination 16.2%F/R/TAF + LDV/SOF NCT02707601 · Phase 3 · registry result, not featured evidence · combination 10.7%Part 1 Randomized Cohort TAF NCT01967940 · Phase 3 · registry result, not featured evidence 0%Part 1 Sentinel Cohort TAF NCT01967940 · Phase 3 · registry result, not featured evidence 10.8%Part 2 E/C/F/TAF + ATV NCT01967940 · Phase 3 · registry result, not featured evidence · combination 16.2%HIV-Suppressed NCT02071082 · Phase 3 · registry result, not featured evidence 0%HIV/HBV Treatment-Naive NCT02071082 · Phase 3 · registry result, not featured evidence 4.8%Cohort 1: E/C/F/TAF+DRV NCT01968551 · Phase 3 · registry result, not featured evidence · combination 10.1%Cohort 2: E/C/F/TAF+DRV NCT01968551 · Phase 3 · registry result, not featured evidence · combination 6%E/C/F/TAF (12 - 17 Years of Age) NCT02276612 · Phase 2/3 · registry result, not featured evidence 0%E/C/F/TAF (≥ 18 Years of Age) NCT02276612 · Phase 2/3 · registry result, not featured evidence 7.7%Group 1: SC LEN+(F/TAF→ TAF) NCT04143594 · Phase 2 · registry result, not featured evidence · combination 7.5%Group 2: SC LEN + (F/TAF → BIC) NCT04143594 · Phase 2 · registry result, not featured evidence · combination 13.5%Group 3: Oral LEN + F/TAF NCT04143594 · Phase 2 · registry result, not featured evidence · combination —BIC + F/TAF NCT02397694 · Phase 2 · registry result, not featured evidence · combination 6.2%BIC + F/TAF (Double-Blind Randomiz NCT02397694 · Phase 2 · registry result, not featured evidence · combination 10.7% NCT01497899 · Phase 2 · registry result, not featured evidence 4.9% NCT01565850 · Phase 2 · registry result, not featured evidence 18.2% NCT03960645 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | e pharyngitis 20.2% (placebo 22.9%) parasitic infection intestinal 18.8% (placebo 17.6%) alanine aminotransferase increased 12.3% (placebo 12.6%) NCT00458393 · Phase 3 show 13 more resultserectile dysfunction 4.8% gastroenteritis 4.8% headache 4.8% NCT02401230 · Phase 4 · registry result, not featured evidence · combination gastroenteritis 5.3% pulmonary embolism 5.3% anxiety 0% NCT02401230 · Phase 4 · registry result, not featured evidence neutrophil count decreased 38% blood albumin decreased 35.6% blood sodium decreased 34% NCT01380080 · Phase 4 · registry result, not featured evidence upper respiratory tract infection 9% diarrhea 8.4% cough 5.2% NCT00724711 · Phase 4 · registry result, not featured evidence · combination diarrhoea 9.7% abdominal pain 4.2% bronchitis 4.2% NCT00323492 · Phase 4 · registry result, not featured evidence 100 mg diarrhoea 18.8% upper respiratory tract infection 16.7% headache 16.4% NCT02275780 · Phase 3 · registry result, not featured evidence 1200 mg QD + Truvada headache 15.8% nausea 13.6% diarrhoea 13.4% NCT02131233 · Phase 3 · registry result, not featured evidence · combination diarrhoea 22.1% jaundice 22.1% ocular icterus 20.1% NCT01108510 · Phase 3 · registry result, not featured evidence · combination bilateral arm pain 2.5% cellulitis 2.5% diarrhoea 2.5% NCT01195467 · Phase 3 · registry result, not featured evidence blood phosphorus decreased 19.4% (placebo 18.3%) aspartate aminotransferase increased 13.1% (placebo 11.5%) headache 13.1% (placebo 14.3%) NCT00625404 · Phase 3 · registry result, not featured evidence 400 mg b.i.d. nasopharyngitis 26.7% headache 26% diarrhoea 25.6% NCT00369941 · Phase 3 · registry result, not featured evidence cough 23.1% neutrophil count decreased 23.1% rash 23.1% NCT00089505 · Phase 3 · registry result, not featured evidence neutrophil count decreased 27.3% rash 26.5% cough 24.1% NCT00089505 · Phase 3 · registry result, not featured evidence | f upper respiratory tract infection 16.2% diarrhoea 13.2% nasopharyngitis 12.9% NCT02121795 · Phase 3 · combination show 45 more resultsupper respiratory tract infection 40% respiratory tract infection 38% nausea 30% NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3 upper respiratory tract infection 26.9% vomiting 25% respiratory tract infection 21.2% NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3 upper respiratory tract infection 51.9% cough 33.3% nasopharyngitis 18.5% NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3 diarrhoea 20.6% headache 17.8% nasopharyngitis 15.9% NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3 diarrhoea 17.2% upper respiratory tract infection 14.6% headache 14% NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3 syphilis 8.7% covid-19 7.9% nasopharyngitis 7.1% NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3 nasopharyngitis 15.5% upper respiratory tract infection 11.6% diarrhoea 9.2% NCT03110380 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 7.2% arthralgia 3.2% bronchitis 3.2% NCT03110380 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 8.6% diarrhoea 6% fatigue 6% NCT03110380 · Phase 3 · registry result, not featured evidence · combination upper respiratory tract infection 14.6% headache 11% anaemia 7.3% NCT01705574 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 17.3% headache 17% nausea 14.9% NCT01705574 · Phase 3 · registry result, not featured evidence nasopharyngitis 10.9% back pain 8.2% diarrhoea 7.3% NCT02616783 · Phase 3 · registry result, not featured evidence arthralgia 9% diarrhoea 4.5% headache 4.5% NCT02605954 · Phase 3 · registry result, not featured evidence diarrhoea 10.4% headache 8.2% vitamin d deficiency 7.1% NCT02605954 · Phase 3 · registry result, not featured evidence urinary tract infection 13.5% upper respiratory tract infection 12.2% arthralgia 9.5% NCT02707601 · Phase 3 · registry result, not featured evidence · combination cough 13.5% headache 10.8% nausea 8.1% NCT02707601 · Phase 3 · registry result, not featured evidence · combination hyperbilirubinaemia 3.6% (placebo 0%) influenza 3.6% (placebo 0%) jaundice 3.6% (placebo 0%) NCT01967940 · Phase 3 · registry result, not featured evidence nausea 16.7% (placebo 0%) arthralgia 8.3% (placebo 0%) diarrhoea 8.3% (placebo 0%) NCT01967940 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 29.7% (placebo 0%) malaria 13.5% (placebo 0%) headache 10.8% (placebo 0%) NCT01967940 · Phase 3 · registry result, not featured evidence · combination upper respiratory tract infection 23% nasopharyngitis 12.2% diarrhoea 10.8% NCT02071082 · Phase 3 · registry result, not featured evidence dental caries 33.3% diarrhoea 33.3% herpes zoster 33.3% NCT02071082 · Phase 3 · registry result, not featured evidence acute sinusitis 19% bronchitis 14.3% sinusitis 14.3% NCT01968551 · Phase 3 · registry result, not featured evidence · combination back pain 12.4% upper respiratory tract infection 11.2% bronchitis 6.7% NCT01968551 · Phase 3 · registry result, not featured evidence · combination cough 24% upper respiratory tract infection 22% vomiting 16% NCT02276612 · Phase 2/3 · registry result, not featured evidence upper respiratory tract infection 60% cough 50% nasal obstruction 30% NCT02276612 · Phase 2/3 · registry result, not featured evidence injection site erythema 48.1% injection site swelling 32.7% injection site pain 28.8% NCT04143594 · Phase 2 · registry result, not featured evidence · combination injection site erythema 34% injection site swelling 34% injection site pain 26.4% NCT04143594 · Phase 2 · registry result, not featured evidence · combination covid-19 21.2% influenza 21.2% headache 17.3% NCT04143594 · Phase 2 · registry result, not featured evidence · combination diarrhoea 13.8% upper respiratory tract infection 10.8% headache 9.2% NCT02397694 · Phase 2 · registry result, not featured evidence · combination nausea 22.3% diarrhoea 17% fatigue 16.1% NCT01497899 · Phase 2 · registry result, not featured evidence diarrhoea 21.4% upper respiratory tract infection 15.5% fatigue 13.6% NCT01565850 · Phase 2 · registry result, not featured evidence back pain 12.1% gestational diabetes 12.1% anaemia 9.1% NCT03960645 · Phase 1 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 2 versus Phase 3.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dTrial phases differ: Phase 3 versus Phase 4.
- ePopulation comparability has not been reviewed for these studies.
- fPopulation comparability has not been reviewed for 47 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Emtricitabine/tenofovir disoproxil fumarate
show 1 more result
show 3 more results
show 3 more results
show 1 more result
+ 10 further endpoints in the CSV export.
Tenofovir alafenamide/emtricitabine
show 6 more results
show 2 more results
show 34 more results
show 9 more results
show 1 more result
show 12 more results
show 5 more results
show 2 more results
show 5 more results
show 26 more results
+ 16 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Emtricitabine/tenofovir disoproxil fumarate's landscape · Tenofovir alafenamide/emtricitabine's landscape